Lancet Article: nilotinib continues to our perform imatinib

google.com/mail/?shva=1#inbox/132e3063c0da6710">https://mail.google.com/mail/?shva=1#inbox/132e3063c0da6710

Nilotinib Versus Imatinib for the Treatment of Patients With Newly Diagnosed Chronic Phase, Philadelphia Chromosome-Positive, Chronic Myeloid Leukaemia: 24-Month Minimum Follow-Up of the Phase 3 Randomised ENESTnd Trial

Lancet Oncol. 2011 Sept 1;12(9):841-851, HM Kantarjian, A Hochhaus, G Saglio, CD Souza, IW Flinn, L Stenke, YT Goh, G Rosti, H Nakamae, NJ Gallagher, A Hoenekopp, RE Blakesley, RA Larson, TP Hughes

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70201-7/abstract